Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw some unusual options trading on Tuesday. Traders bought 13,196 call options on the company. This represents an increase of approximately 374% compared to the average volume of 2,782 call options.

Hedge Funds Weigh In On Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Up 13.0 %

RVPH opened at $2.00 on Wednesday. The business has a 50 day moving average price of $1.67 and a two-hundred day moving average price of $1.32. The company has a market cap of $66.88 million, a PE ratio of -1.80 and a beta of -0.12. Reviva Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $4.83.

Wall Street Analysts Forecast Growth

A number of research firms have commented on RVPH. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Friday, January 10th. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday. Finally, Roth Mkm initiated coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 target price for the company. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $12.00.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.